Close Menu

NEW YORK – Bio-Path Holdings has dosed the first patient in its Phase I clinical trial evaluating BP1002, a BCL-2 inhibitor, as a treatment for refractory/relapsed lymphoma and chronic lymphocytic leukemia (CLL) patients.

The trial has enrolled six patients to evaluate BP1002 as a monotherapy. The primary endpoints are determining the safety and tolerability of escalating doses of BP1002, the recommended Phase 2 dose of BP1002, pharmacokinetics of BP1002, and BP1002 activity on BCL-2 expression. Secondary endpoints are measurements of tumor response.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Sponsored by
Qiagen

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.